Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX4 | Q99571 | 15/20 | 0.68 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30297204 | 1.00 | P2RX4 (0.68) | P2RX4MAPTTSHRHSD17B10LMNA | |
| SCHEMBL16239620 | 0.92 | P2RX4 (0.64) | P2RX4MAPTTSHRLMNAMAPK1 | |
| SCHEMBL30297229 | 0.92 | P2RX4 (0.64) | P2RX4MAPTTSHRLMNAMAPK1 | |
| SCHEMBL18543697 | 0.88 | P2RX4 (0.71) | P2RX4 | |
| SCHEMBL30297299 | 0.86 | P2RX4 (0.84) | P2RX4 | |
| SCHEMBL16239201 | 0.86 | P2RX4 (0.84) | P2RX4 | |
| SCHEMBL16238979 | 0.85 | P2RX4 (0.66) | P2RX4MAPT | |
| SCHEMBL30297303 | 0.85 | P2RX4 (0.66) | P2RX4MAPT | |
| SCHEMBL16239100 | 0.85 | P2RX4 (0.73) | P2RX4 | |
| SCHEMBL30297298 | 0.85 | P2RX4 (0.73) | P2RX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260000678-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING, SUPPRESSING, OR TREATING SYMPTOM ASSOCIATED WITH PSEUDO-ALLERGIC REACTION | TAKASAKI UNIV OF HEALTH AND WELFARE (JP) | 2026-01-01 | — | — | US | claimed |
| US-20250375456-A1 | AGENT FOR PREVENTING OR TREATING RESPIRATORY DISEASE | NIPPON CHEMIPHAR CO (JP) | 2025-12-11 | — | — | US | claimed |
| US-20250241927-A1 | MEDICAMENT COMPRISING A P2X4 RECEPTOR ANTAGONIST FOR PREVENTING OR TREATING NOCICEPTIVE PAIN AND/OR VISCERAL PAIN | NIPPON CHEMIPHAR CO (JP) | 2025-07-31 | — | — | US | claimed |
| EP-4501357-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR SUPPRESSING OR TREATING SYMPTOMS ACCOMPANYING PSEUDO-ALLERGIC REACTIONS | Takasaki University of Health and Welfare (JP) | 2025-02-05 | — | — | EP | claimed |
| WO-2024177158-A1 | SOLID DISPERSION OF COMPOUND HAVING P2X4 RECEPTOR ANTAGONISM | 日本ケミファ株式会社 | 2024-08-29 | — | — | WO | claimed |
| EP-4410310-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR RESPIRATORY DISEASES | Nippon Chemiphar Co., Ltd. (JP) | 2024-08-07 | — | — | EP | claimed |
| US-11918589-B2 | Medicament for treatment of multiple sclerosis | NIPPON CHEMIPHAR CO., LTD. (JP) | 2024-03-05 | — | — | US | claimed |
| US-20230277552-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING, SUPPRESSING, OR TREATING SYMPTOM ASSOCIATED WITH ALLERGIC REACTION | NIPPON CHEMIPHAR CO., LTD. (JP) | 2023-09-07 | — | — | US | claimed |
| EP-4190356-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING, SUPPRESSING, OR TREATING SYMPTOMS ASSOCIATED WITH ALLERGIC REACTION | Nippon Chemiphar Co., Ltd. (JP) | 2023-06-07 | — | — | EP | claimed |
| US-20230149421-A1 | MEDICAMENT FOR PREVENTING OR TREATING IRRITABLE BOWEL SYNDROME OR INFLAMMATORY BOWEL DISEASE | NIPPON CHEMIPHAR CO., LTD. (JP) | 2023-05-18 | — | — | US | claimed |
| EP-4129296-A1 | DRUG FOR PREVENTION OR TREATMENT OF IRRITABLE BOWEL SYNDROME OR INFLAMMATORY BOWEL DISEASE | Università di Pisa (IT) | 2023-02-08 | — | — | EP | claimed |
| EP-3848051-A1 | MEDICINE FOR DIABETIC PERIPHERAL NEUROPATHY | Nippon Chemiphar Co., Ltd. (JP) | 2021-07-14 | — | — | EP | claimed |
| US-20210121478-A1 | MEDICAMENT FOR TREATMENT OF MULTIPLE SCLEROSIS | NIPPON CHEMIPHAR CO., LTD. (JP) | 2021-04-29 | — | — | US | claimed |
| US-20200223806-A1 | P2X4 RECEPTOR ANTAGONIST | NIPPON CHEMIPHAR CO., LTD (JP) | 2020-07-16 | — | — | US | claimed |
| EP-2803662-B1 | P2X4 RECEPTOR ANTAGONIST | NIPPON CHEMIPHAR CO (JP) | 2017-03-01 | — | — | EP | claimed |
| US-20160280667-A1 | P2X4 RECEPTOR ANTAGONIST | NIPPON CHEMIPHAR CO., LTD (JP) | 2016-09-29 | — | — | US | claimed |
| US-12629379-B2 | Pharmaceutical composition for preventing, suppressing, or treating symptom associated with allergic reaction | NIPPON CHEMIPHAR CO., LTD. (JP) | 2026-05-19 | — | — | US | disclosed |
| US-20260000678-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING, SUPPRESSING, OR TREATING SYMPTOM ASSOCIATED WITH PSEUDO-ALLERGIC REACTION | TAKASAKI UNIV OF HEALTH AND WELFARE (JP) | 2026-01-01 | — | — | US | disclosed |
| US-20140357858-A1 | P2X4 RECEPTOR ANTAGONIST | NIPPON CHEMIPHAR CO., LTD (JP) | 2014-12-04 | — | — | US | disclosed |
| EP-2803662-A1 | P2X4 RECEPTOR ANTAGONIST | Nippon Chemiphar Co., Ltd. (JP) | 2014-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250375456-A1 | AGENT FOR PREVENTING OR TREATING RESPIRATORY DISEASE | P2RX5, P2RX3, P2RX2 | P2RX4 7/4885MAPT 4612/4885TSHR 3356/4885 |
| US-20210121478-A1 | MEDICAMENT FOR TREATMENT OF MULTIPLE SCLEROSIS | TRPM4, TRPM7, P2RX3 | P2RX4 5/4885MAPT 1093/4885TSHR 4070/4885 |
| US-20160280667-A1 | P2X4 RECEPTOR ANTAGONIST | P2RX7, P2RX1, P2RX2 | P2RX4 6/4885MAPT 4720/4885TSHR 582/4885 |
| US-20140357858-A1 | P2X4 RECEPTOR ANTAGONIST | P2RX7, P2RX1, P2RX2 | P2RX4 6/4885MAPT 4724/4885TSHR 584/4885 |
| US-20200223806-A1 | P2X4 RECEPTOR ANTAGONIST | P2RX7, P2RX1, P2RX2 | P2RX4 6/4885MAPT 4724/4885TSHR 584/4885 |
| US-11918589-B2 | Medicament for treatment of multiple sclerosis | P2RX3, TRPM4, P2RX4 | P2RX4 3/4885MAPT 1199/4885TSHR 3931/4885 |
| US-12629379-B2 | Pharmaceutical composition for preventing, suppressing, or treating symptom associated with allergic reaction | HRH2, HRH4, HRH1 | P2RX4 19/4885MAPT 4036/4885TSHR 1940/4885 |
| US-20260000678-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING, SUPPRESSING, OR TREATING SYMPTOM ASSOCIATED WITH PSEUDO-ALLERGIC REACTION | TRPV1, TRPV4, TRPV5 | P2RX4 15/4885MAPT 1187/4885TSHR 1896/4885 |
| US-20230277552-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING, SUPPRESSING, OR TREATING SYMPTOM ASSOCIATED WITH ALLERGIC REACTION | P2RX5, P2RX3, P2RX2 | P2RX4 4/4885MAPT 3836/4885TSHR 2372/4885 |
| US-20230149421-A1 | MEDICAMENT FOR PREVENTING OR TREATING IRRITABLE BOWEL SYNDROME OR INFLAMMATORY BOWEL DISEASE | P2RX5, P2RX3, P2RX2 | P2RX4 5/4885MAPT 4023/4885TSHR 4117/4885 |
| US-20250241927-A1 | MEDICAMENT COMPRISING A P2X4 RECEPTOR ANTAGONIST FOR PREVENTING OR TREATING NOCICEPTIVE PAIN AND/OR VISCERAL PAIN | P2RX3, TRPV1, P2RX2 | P2RX4 5/4885MAPT 3834/4885TSHR 3330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.